In reaponse to all the concerns, the deals is grea

In reaponse to all the concerns, the deals is great on paper. So long as we don't start to prioritize or allocate funding to these programs over others, there is no negative impact to assuming the miniscule debt. I think reaquisition of the diagnostics has been in the plans for a long time. And you guys are mixing up facts. In the new agreement we weren't giving up the 80 M shares to the toxics.

Goix and gc have a relationship. As soon as it was clear that the spinoff wouldn't succeed, I'm sure they were gonna find a way to bring it back in. I was never certain but publicly speculated as such several times this fall once goix had joined and especially after gc abrubtly left the Avant b.o.d with their stock price lingering newly at our low prices, and the news that msprecise was trying to wogle out of the license. Now the tables have turned once again and we seem to have the upper hand.

I'm sure the folks at theranostics had no intention of advancing anything science or product wise while still in the relationship with the parties that for one reason or another. Now they should feel free to chart their own house, but I will not be surprised if we now find a way to muscle them in under our umbrella's 4th leg. Then we will in fact be revenue producing. But no promises, just thoughts. Sign have been there, but the fundamental driver is that we had something of value that had turned into nothing.